This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

John Zuris, PhD
Associate Director, Editing Technologies at Editas Medicine


John Zuris is Associate Director of Editing Technologies at Editas Medicine, a genome editing company focused on using CRISPR technology to treat patients suffering from severe diseases. His group leverages Editas’s proprietary engineered AsCas12a nuclease to achieve the best editing outcome for a chosen indication. His group developed methods to achieved nearly 100% efficiency for gene disruption or gene insertion, potentially generating best-in-class cell-based medicines. Prior to joining Editas Medicine, John completed his postdoctoral training in the laboratory of Dr. David Liu (Harvard University-Broad Institute) where he developed a lipid nanoparticle delivery system for CRISPR-Cas9 which allows for highly efficient genome editing in ex vivo and in vivo applications.

Agenda Sessions

  • A Method for Highly Efficient Knock-in and Expression of Transgene Cargos for Next- Generation Cell-based Medicines